

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MPM BIOVENTURES III LLC</u> (Last) (First) (Middle) C/O MPM ASSET MANAGEMENT 200 CLARENDON ST., 54TH FLOOR (Street) BOSTON MA 02116 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>HEALTHCARE ACQUISITION CORP [HAQ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/03/2007	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/03/2007		j ⁽¹⁾		3,218,250 ⁽¹⁾	A	(1)	3,343,250	I	See Footnote ⁽²⁾
Common Stock	08/07/2007		P		125,000 ⁽³⁾	A	\$7.7	3,468,250	I	See Footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
8% Convertible Note	\$10	08/03/2007		j ⁽⁵⁾		\$4,702,960.41		(6)	08/03/2009	Common Stock	470,296	(5)	\$4,702,960.41	I	See Footnote ⁽⁷⁾

1. Name and Address of Reporting Person*
MPM BIOVENTURES III LLC
 (Last) (First) (Middle)
 C/O MPM ASSET MANAGEMENT
 200 CLARENDON ST., 54TH FLOOR
 (Street)
 BOSTON MA 02116
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MPM BIOVENTURES III PARALLEL FUND, LP
 (Last) (First) (Middle)
 C/O MPM ASSET MANAGEMENT
 200 CLARENDON ST., 54TH FLOOR
 (Street)
 BOSTON MA 02116
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
 (Last) (First) (Middle)
 C/O MPM ASSET MANAGEMENT

200 CLARENDON ST., 54TH FLOOR

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BIOVENTURES III LP](#)

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BIOVENTURES III GP LP](#)

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BIOVENTURES III QP LP](#)

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM Asset Management Investors 2004 BVIII LLC](#)

(Last)

(First)

(Middle)

C/O MPM ASSET MANAGEMENT
200 CLARENDON ST., 54TH FLOOR

(Street)

BOSTON MA 02116

(City)

(State)

(Zip)

Explanation of Responses:

1. The shares were received in exchange for an aggregate of 17,933,960 shares of Series B and Series C Convertible Preferred Stock of PharmAthene, Inc. in connection with the acquisition of PharmAthene, Inc. through the merger of the Issuer's subsidiary into PharmAthene, Inc. (the "Merger"). The shares were received as follows: 2,669,130 by MPM BioVentures III-QP, L.P. ("BV III QP"), 179,482 by MPM BioVentures III, L.P. ("BV III"), 63,454 by MPM Asset Management Investors 2004 BVIII LLC ("AM 2004"), 80,617 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 225,567 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadick, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2004. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
2. The shares are held as follows: 2,772,802 by BV III QP, 186,453 by BV III, 65,919 by AM 2004, 83,748 by BV Parallel and 234,328 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
3. The shares were purchased as follows: 103,672 by BV III QP, 6,971 by BV III, 2,465 by AM 2004, 3,131 by BV Parallel and 8,761 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
4. The shares are held as follows: 2,876,474 by BV III QP, 193,424 by BV III, 68,384 by AM 2004, 86,879 by BV Parallel and 243,089 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
5. The notes were received in the Merger in cancellation of convertible promissory notes of PharmAthene, Inc. in the aggregate principal amount of \$4,425,867.53, plus accrued interest thereon.
6. Immediately convertible into shares of Common Stock of the Issuer at the rate of \$10.00 per share.
7. The notes are held as follows: \$3,900,508.33 by BV III QP, \$262,284.12 by BV III, \$92,728.30 by AM 2004, \$117,808.98 by BV Parallel and \$329,630.69 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Remarks:

See Form 4 for Luke Evnin for additional members of this joint filing.

[/s/ Luke Evnin, Series A Member](#) 08/07/2007
[of MPM BioVentures III LLC](#)

[/s/ Luke Evnin, Series A Member](#) 08/07/2007

<u>of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, the general partner of MPM BioVentures III Parallel Fund, LP</u>	
<u>/s/ Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, in its capacity as the Managing Limited Partner of MPM BioVentures III GmbH & Co. Beteiligungs KG</u>	<u>08/07/2007</u>
<u>/s/ Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, the general partner of MPM BioVentures III, LP</u>	<u>08/07/2007</u>
<u>/s/ Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP</u>	<u>08/07/2007</u>
<u>/s/ Luke Evnin, Series A Member of MPM BioVentures III LLC, the general partner of MPM BioVentures III GP, LP, the general partner of MPM BioVentures III QP, LP</u>	<u>08/07/2007</u>
<u>/s/ Luke Evnin, manager of MPM Asset Management Investors 2004 BVIII LLC</u>	<u>08/07/2007</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.